Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma By Ogkologos - May 14, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the RMC-6236-001 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) New ESMO President 2029-2030 Elected MOST POPULAR High Jumper Training for Her Fifth Olympics Uses Personal Breast Cancer... December 9, 2020 Advanced MRI could help to differentiate aggressive and slower growing prostate... February 14, 2022 ESMO Congress 2024 Barcelona, Spain, 13-17 September September 3, 2024 New Technology System Allows Patients To Get A Mammogram And Biopsy... June 30, 2020 Load more HOT NEWS Triple Blockade Demonstrates High Response Rates in Metastatic Melanoma Ενθαρρυντικά δεδομένα για ασθενείς με προχωρημένο μελάνωμα που έλαβαν θεραπεία με... ΜΕΛΑΝΩΜΑ Mathew Knowles, Father Of Beyoncé, Fought And Beat Breast Cancer
